Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC targets child supplement claims

This article was originally published in The Tan Sheet

Executive Summary

Manufacturers of dietary supplements carrying health claims for children "can expect to see more [advertising regulatory] activity in this area" in the near future, Federal Trade Commission Associate Director for Advertising Practices Mary Engle says at American Herbal Products Association members breakfast Sept. 4. Engle attributes "grave concern" in Congress about dietary supplement advertising to children as spurring likely upcoming FTC actions. The House Energy & Commerce/Oversight & Investigations Subcommittee discussed legislation to give FDA more access to dietary supplement safety information and greater leniency to protect consumers from potentially unsafe products at July 23 meeting (1"The Tan Sheet" July 28, 2003, p. 3)...

You may also be interested in...

Supplement Bill Increasing FDA Access To Safety Data Planned By Waxman

Reps. Henry Waxman (D-Calif.) and Susan Davis (D-Calif.) are working on legislation "that will give FDA greater access to information to understand if a [dietary supplement] product does pose a health risk and will let FDA protect consumers from unsafe products," Waxman said at a July 23 hearing of the House Energy & Commerce/Oversight & Investigations Subcommittee

BMS, Eisai Team Up To Accelerate Development Of Solid-Tumor ADC

The US firm gets development and co-commercial rights to MORAb-202 for $650m up front. BMS joins AstraZeneca, Merck & Co. and Gilead in recent ADC deal-making.

BIO 2021 Notebook: Best Practices For Business Development

The recently concluded BIO annual meeting included several sessions focused on the practice of business development. In this extra edition of our BIO 2021 notebook, Scrip collected observations about best practices for partnerships.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts